Oct 12 2022

Halberd Progresses from Eliminating Top Brain Disease Antigens from CSF To Eradication of Interleukin-6 From Human Blood Serum

By |2022-10-11T20:09:20-04:00October 12th, 2022|Investor News, News, Press Releases, Uncategorized|0 Comments

Excess IL-6 is associated with inflammation in rheumatoid arthritis, MS, some cancers and neurodegenerative diseases. Jackson Center, PA, October 12, 2022 – Halberd Corporation (OTC-PINK: "HALB”) demonstrated the removal of Interleukin-6 (IL-6) from human blood serum during in-vitro laboratory studies.  Excess Interleukin-6 in the blood has been linked to numerous adverse health conditions. Unlike Halberd’s ...

May 24 2022

Halberd Successfully Eliminates Excess Levels of Inflammatory Cytokines

By |2022-05-24T05:22:45-04:00May 24th, 2022|Featured, Investor News, News|0 Comments

Jackson Center, PA, May 24, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have demonstrated a protocol which allows for the precise level of elimination of a specific targeted cytokine from a homogeneous mixture of two different cytokines in a fluid.  Several adverse health conditions are caused by excess quantities of particular components in blood or ...

Dec 6 2021

Halberd Follow-up Verification Tests Prove 100% Eradication of TNF-alpha, a Major Contributing Factor to Alzheimer’s Disease and PTSD/CTE

By |2021-12-05T19:03:46-05:00December 6th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, December 6, 2021 – Halberd Corporation (OTC PINK:HALB) completed verification tests on elimination of Tumor Necrosis Factor-alpha (TNF-alpha) from synthetic cerebral spinal fluid (CSF).  These tests confirmed virtually 100% elimination of TNF-alpha through Halberd’s patented extracorporeal process, in combination with its patent-pending exposure to tuned laser irradiation.  TNF-alpha is an inflammatory cytokine ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Go to Top